None listed
Conditions
Interventions
Loading dose of 600mg of hydroxychloroquine orally, followed by 400mg of hydroxychloroquine every other day for 8 weeks and use of measures of personal protection.
Group name:Arm 2 Type of group
Use of measures of personal protection.
Sponsors
UNIVERSIDAD PERUANA CAYETANO HEREDIA,
Eligibility
Inclusion criteria
Inclusion criteria: A. Healthcare workers in service during the COVID-19 outbreak including medical, nurse, technical and auxiliary staff. B. Negative rapid serologic and molecular testing for SARS-CoV-2. C. Written informed consent.
Exclusion criteria
Exclusion criteria: A. Presents COVID-19 symptoms including cough, fever, myalgias, headaches, loss of smell and taste B. Prior (last 30 days) or current (or planned use during the study period) use of hydroxychloroquine, chloroquine sulfate or azithromycin. C. Known history of prolonged QT syndrome. D. Known allergy or intolerance to hydroxychloroquine. E. Use of concomitant medications that are contraindicated with the use of hydroxychloroquine. F. Participation might not be beneficial, by investigator judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Positive confirmatory or serologic testing for SARS-CoV-2 Measure:Efficacy Timepoints:4 and 8 weeks ; Outcome name:Proportion of patients with grade 3 or more adverse events Measure:Safety Timepoints:4 and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Proportion of participants that discontinue prophylactic treatment due to grade 1 o 2 adverse events Measure:Tolerability Timepoints:4 and 8 weeks | — |
Countries
Peru
Contacts
Public ContactAlvaro Schwalb
UNIVERSIDAD PERUANA CAYETANO HEREDIA
Outcome results
None listed